Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.
about
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)Activation of the aryl hydrocarbon receptor by the widely used Src family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2).Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism.The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.Mechanisms of xenobiotic receptor activation: Direct vs. indirect.Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-κB.5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-κB-dependent mechanism.Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway.Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Differential Effects of Sunitinib on the Expression Profiles of Xenobiotic-Metabolizing Enzymes and Transporters in Rat Liver and Kidneys.Commentary: Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways
P2860
Q34570873-2DC473D3-42ED-4621-B786-D5C5569842FFQ35680450-7CE617BA-8254-4BBB-8E70-1BF70C1587BDQ36027841-0AE30FB0-262E-45E5-9F2C-0F4705920F4EQ38714257-5BD21AE4-5BBA-49A4-AB23-6A231406E1F3Q38733688-11A54619-162A-474C-AB78-4EBEB216E48AQ38825803-978BFB33-68BF-40CF-BA07-3C338B7B343EQ38918680-79AD4E98-8225-431A-A8B5-BE1E705D4647Q42708298-F199B294-AD33-4FE7-9E31-ADEAF58E4A6EQ46373476-C35C4E27-966F-4EDE-8792-36F5ACEA03EEQ48306032-A5FB62C8-A94C-4214-9825-0224FB8045C0Q49185697-31FE1028-0292-467E-9FBE-614A27FDF962Q50091855-0B238673-AEA8-4FB2-8C83-EACFD88EC2D4Q53202969-65299EE0-1E69-4B5E-B99B-DB1E677F0BC8Q58735041-54066C34-618A-44FE-AB06-44D50754EA0AQ58764297-0A4C6589-F9BE-4CB9-9154-E0DD7AAEC768
P2860
Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Sunitinib, a tyrosine kinase i ...... drocarbon receptor activation.
@en
Sunitinib, a tyrosine kinase i ...... drocarbon receptor activation.
@nl
type
label
Sunitinib, a tyrosine kinase i ...... drocarbon receptor activation.
@en
Sunitinib, a tyrosine kinase i ...... drocarbon receptor activation.
@nl
prefLabel
Sunitinib, a tyrosine kinase i ...... drocarbon receptor activation.
@en
Sunitinib, a tyrosine kinase i ...... drocarbon receptor activation.
@nl
P2093
P2860
P1476
Sunitinib, a tyrosine kinase i ...... drocarbon receptor activation.
@en
P2093
Ayman O El-Kadi
Hesham M Korashy
Mohamed A M El Gendy
Zaid H Maayah
P2860
P2888
P304
P356
10.1007/S00204-012-0996-Y
P577
2013-01-04T00:00:00Z